Læknablaðið - 15.12.2010, Blaðsíða 24

F R Æ Ð I G R E I
RANNSÓKN
N A R
MR
lyfjameðferð heilsukvíðans og annarrar tengdrar
röskunar.32'34 Sérstaklega ber að nefna nýlega
rannsókn sem sýndi fram á áþekkan árangur
með paroxetín og hugrænni atferlismeðferð gegn
heilsukvíða.35 í töflu III má sjá yfirlit yfir helstu
lyf og skammta sem notuð eru við heilsukvíða.
Algengt er að það þurfi að nota nokkuð háa
skammta en eigi að síður er nauðsynlegt að
byrja hægt þar sem heilsukvíðnir eru sérstaklega
viðkvæmir fyrir aukaverkunum, ekki síst í byrjun
meðferðar.33-36-37
Þakkir
Höfundarnir þakka Aðalheiði D. Matthíasdóttur,
Pétri Berg Matthíassyni og Helenu Jónsdóttur
fyrir yfirlestur greinarinnar og góðar ábendingar.
Heimildir
1. American Psychiatric Association. Diagnostic and statistical
manual of mental disorders (4th ed., text rev.).: APA,
Washington DC 2000.
2. Simon G. Psychiatric disorders and functional somatic
symptoms as predictors of health care use. Psychiatr Med
1992; 10: 49-59.
3. Barsky AJ, Wyshak G, Latham KS, Klerman GL.
Hypochondriacal patients, their physicians, and their
medical care. J Gen Intem Med 1991; 6: 413-9.
4. Magarinos M, Zafar U, Nissenson K, Blanco C. Epidemiology
and treatment of hypochondriasis. CNS Drugs 2002; 16: 9-22.
5. Barsky AJ. Clinical practice. The patient with
hypochondriasis. N Engl J Med. 2001; 345:1395-9.
6. Barsky AJ, Wyshak G, Klerman GL, Latham KS. The
prevalence of hypochondriasis in medical outpatients. Soc
Psychiatry Psychiatr Epidemiol 1990; 25: 89-94.
7. Kellner R. Hypochondriasis and somatization. JAMA 1987;
258: 2718-22.
8. Barsky AJ. The validity of bodily symptoms in medical
outpatients. In: Stone AA, Turkkan JS, Bachrach CA, Jobe
JB, Kurtzman HS, Cain VS eds. The science of self-report:
Implications for research and practice. Mahwah, NJ:
Erlbaum, 2000: 339-61.
9. Kellner R. Somatization and hypochondriasis. Praeger, New
York 1986.
10. Faravelli C, Salvatori S, Galassi F, Aiazzi L, Drei C, Cabras
P. Epidemiology of somatoform disorders: a community
survay in Florence. Soc Psychiatry Psychiatr Epidemiol 1997;
32: 24-9.
11. Gureje O, Ustum TB, Simon GE. The syndrome of
hypochondriasis: a cross-national study in primary
care. Psychol Med 1997; 27:1001-10.
12. Salkovskis PM, Warwick HMC. Making sense of
hypchondriasis: A cognitive model of health anxiety. In
Asmundson GJG, Taylor S, Cox BJ (Eds.) Health anxiety:
Clinical and research perspectives on hypochondriasis and
related conditions. John Wiley & Sons Ltd, New York 2001:
46-64.
13. Haenen MA, de Jong PJ, Schmidt AJ, Stevens S, Visser L.
Hypochondriacs' estimation of negative outcomes: domain-
specificity and responsiveness to reassuring and alarming
information. Behav Res Ther 2000; 38: 819-33.
14. Rief W, Hiller W, Margraf J. Cognitive aspects of
hypochondriasis and the somatization syndrome. J Abnorm
Psychol 1998; 107: 587-95.
15. Wells A. Cognitive Therapy of Anxiety Disorders. John Wiley
& Sons, Chichester 1997.
16. Brown HD, Kosslyn SM, Delamater B, Fama J, Barsky AJ.
Perceptual and memory biases for health-related information
in hypochondriacal individuals. J Psychosom Res 1999; 47:
67-78.
17. Pauli P, Alpers GW. Memory bias in patients with
hypochondriasis and somatoform pain disorder. J Psychosom
Res 2002; 52: 45-53.
18. Miller SM, Brody DS, Summerton J. Styles of coping with
threat: implications for health. J Pers Soc Psychol 1988; 54:
142-8.
19. Haenen MA, Schmidt AJ, Kroeze S, van den Hout MA.
Hypochondriasis and symptom reporting - the effect of
attention versus distraction. Psychother Psychosom 1996; 65:
43-8.
20. Taylor S, Asmundson GJG. Treating Health Anxiety: A
Cognitive-Behavioral Approach. The Guilford Press, New
York 2004.
21. Salkovskis PM, Warwick HM. Morbid preoccupations,
health anxiety and reassurance: a cognitive-behavioural
approach to hypochondriasis. Behav Res Ther 1986; 24: 597-
602.
22. Abromowitz JS, Braddock AE. Hypochondriasis:
Conceptualization, Treatment, and Relationship to Obsessive
- Compulsive Disorder. Psychiatr Clin N Am 2006; 29: 503-
19.
23. Starcevic V. Relationship between Hypochondriasis and
Obsessive-Compulsive Personality Disorder: Close Relatives
Seperated by Nosological Schemes? Am J Psychother 1990;
154: 340-7.
24. Greeven A, van Balkom AJ, van Rood YR, van Oppen P,
Spinhoven P. The boundary between hypochondriasis and
obsessive-compulsive disorder: a cross-sectional study from
the Netherlands. J Clin Psychiatry. 2006; 67:1682-9.
25. Fallon BA, Qureshi AI, Laje G, Klein B. Hypochondriasis and
its relationship to obsessive-compulsive disorder. Psychiatr
Clin North Am. 2000; 23: 605-16.
26. Barsky AJ. Hypochondriasis and obsessive compulsive
disorder. Psychiatr Clin North Am. 1992; 15: 791-801.
27. Cohen J. Statistical Power Analysis for the Behavioral
Sciences (2. útg.). Lawrence Erlbaum Associates, Hillsdale
1988.
28. Bouman TK. A community-based psychoeducational group
approach to hypochondriasis. Psychother Psychosom 2002;
71: 326-32.
29. Kroenke K, Swindle R. Cognitive-behavioral therapy for
somatization and symptom syndromes: a critical review of
controlled clinical trials. Psychother Psychosom 2000; 69:
205-15.
30. Clark DM, Salkovskis PM, Hackmann A, et al. Two
psychological treatments for hypochondriasis: a randomised
controlled trial. Br J Psychiatry 1998; 173: 218-25.
31. Stern R, Fernandez M. Group cognitive and behavioural
treatment for hypochondriasis. BMJ 1991; 303:1229-31.
32. Noyes R, Reich J, Clancy J, O'Gorman TW. Reduction in
hypochondriasis with treatment of panic disorder. Br J
Psychiatry 1986; 149: 631-5.
33. Keeley R, Smith M, Miller J. Somatoform symptoms and
treatment nonadherence in depressed family medicine
outpatients. Arch Fam Med 2000; 9: 46-54.
34. Fava GA, Mangelli L. Hypochondriasis and anxiety
disorders. In: Starcevic V, Lipsitt DR, eds. Hypochondriasis:
modem perspectives on an ancient malady. Oxford
University Press, Oxford, England 2001: 89-102.
35. Greeven A, van Balkom AJ, van der Leeden R, Merkelbach
JW, van den Heuvel OA, Spinhoven P. Cognitive
behavioural therapy versus paroxetine in the treatment
of hypochondriasis: an 18-month naturalistic follow-up. J
Behav Ther Exp Psychiatr 2009; 40: 487-96.
36. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden
E, Kroenke K. Antidepressant therapy for unexplained
symptoms and symptom syndromes. J Fam Pract 1999; 48:
980-90.
37. Fallon BA, Schneier FR, Marshall R, et al. The
pharmacotherapy of hypochondriasis. Psychopharmacol
Bull 1996; 32: 607-11.
760 LÆKNAblaöið 2010/96